Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €37.78 EUR
Change Today -0.228 / -0.60%
Volume 0.0
HO1 On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 3:54 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

hologic inc (HO1) Snapshot

Open
€36.89
Previous Close
€38.01
Day High
€37.85
Day Low
€35.38
52 Week High
07/30/15 - €38.28
52 Week Low
10/17/14 - €17.76
Market Cap
10.6B
Average Volume 10 Days
86.0
EPS TTM
--
Shares Outstanding
281.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HOLOGIC INC (HO1)

hologic inc (HO1) Related Businessweek News

No Related Businessweek News Found

hologic inc (HO1) Details

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States and internationally. The company operates in four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment provides Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, instrumentation, Invader chemistry platform, ThinPrep system, fetal fibronectin tests, Procleix family of assays, and virology and infectious disease products. The Breast Health segment provides breast imaging and related products and accessories, including digital and film-based mammography systems; computer-aided detection (CAD) for mammography; invasive breast biopsy devices; breast biopsy site markers; breast biopsy guidance systems; and breast brachytherapy products. This segment also offers Dimensions platform, a mammography gantry for 2D and 3D image acquisition and display; C-View that provides a 2D image; breast MRI coils and workstations; and photoconductor coatings. The GYN Surgical segment provides NovaSure system to treat women suffering from abnormal uterine bleeding; and MyoSure system for the hysteroscopic removal of fibroids. The Skeletal Health segment offers discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient’s extremities, such as the hand, wrist, knee, foot, and ankle. Hologic, Inc. sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. The company has a strategic alliance with Quest Diagnostics Incorporated. Hologic, Inc. was founded in 1985 and is headquartered in Bedford, Massachusetts.

5,351 Employees
Last Reported Date: 11/20/14
Founded in 1985

hologic inc (HO1) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $792.3K
Chief Financial Officer
Total Annual Compensation: $147.1K
Chief Operating Officer
Total Annual Compensation: $199.0K
Compensation as of Fiscal Year 2014.

hologic inc (HO1) Key Developments

Hologic, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 27, 2015; Provides Earnings Guidance for the Fourth Quarter of 2015 and Revises Earnings Guidance for the Full Year of 2015

Hologic Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended June 27, 2015. For the quarter, the company reported total revenues of $693.9 million against $632.6 million a year ago. Income from operations was $116.0 million against $76.2 million a year ago. Income before income taxes was $46.7 million against $22.6 million a year ago. Net income was $29.4 million or $0.10 basic and diluted per share against $11.3 million or $0.04 basic and diluted per share a year ago. Non-GAAP income from operations was $230.3 million against $199.8 million a year ago. Non-GAAP pre-tax income was $193.0 million against $158.1 million a year ago. Non-GAAP net income was $126.9 million or $0.43 diluted per share against $102.4 million or $0.37 diluted per share a year ago. Adjusted EBITDA was $249.7 million against $221.7 million a year ago. Revenues increased 12.2% on a constant currency basis, and grew 10%, including $279.5 million from the breast health business and $306.9 million from the diagnostic testing business. Operating cash flow was $242.3 million, an increase of 53.0%, driven by higher net income and working capital improvements primarily from better inventory management. Free cash flow, defined as operating cash flow less capital expenditures was $223.9 million. For the nine months, the company reported total revenues of $2,002.2 million against $1,870.1 million a year ago. Income from operations was $329.4 million against $187.7 million a year ago. Income before income taxes was $151.8 million against $9.5 million a year ago. Net income was $106.5 million or $0.37 diluted per share against net loss of $10.8 million or $0.04 basic and diluted per share a year ago. Net cash provided by operating activities was $553.6 million against $376.7 million a year ago. Purchase of property and equipment was $27.9 million against $30.9 million a year ago. Non-GAAP income from operations was $665.0 million against $593.8 million a year ago. Non-GAAP pre-tax income was $543.9 million against $459.3 million a year ago. Non-GAAP net income was $357.5 million or $1.24 diluted per share against $299.7 million or $1.08 diluted per share a year ago. Adjusted EBITDA was $721.3 million against $657.6 million a year ago. Revenues increased 12.2% on a constant currency basis, and grew in three of four business segments globally. Return on invested capital was 10.6% on a trailing twelve months basis, compared to 8.3% in the prior year period. Net debt position of $3.053 billion, an improvement of $579 million compared to the prior-year period. Despite a currency headwind, earnings per share increased by 16.2%, significantly faster than revenues and ahead of its most recent guidance and net income grew at an even faster rate, but the translation to EPS was diluted by a higher share count resulting from the convertible notes on its balance sheet and its rising stock price. The company provided earnings guidance for the fourth quarter of 2015 and revised earnings guidance for the full year of 2015. For the quarter, the company expects revenue in the range of between $685 million to $695 million, non-GAAP EPS in the range of between $0.41 to $0.42. Non-GAAP EPS is expected to grow 7.9% to 10.5% on a reported basis or roughly 13.2% to 15.8% in constant currency. For the year, the company expects revenue in the range of between $2,687 million to $2,697 million, non-GAAP EPS in the range of between $1.65 to $1.66 against previous guidance with revenue in the range of between $2,600 million to $2,620 million, non-GAAP EPS in the range of between $1.57 to $1.59. The company estimated annual effective tax rate of 34.25%.

Hologic Inc. to Report Q3, 2015 Results on Jul 29, 2015

Hologic Inc. announced that they will report Q3, 2015 results at 5:00 PM, Eastern Standard Time on Jul 29, 2015

Hologic Inc., Q3 2015 Earnings Call, Jul 29, 2015

Hologic Inc., Q3 2015 Earnings Call, Jul 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HO1:GR €37.78 EUR -0.228

HO1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DENTSPLY International Inc $56.91 USD +0.85
Edwards Lifesciences Corp $152.16 USD -0.94
MEDNAX Inc $84.64 USD +2.63
Mettler-Toledo International Inc $337.60 USD -2.78
Cooper Cos Inc/The $177.00 USD +0.50
View Industry Companies
 

Industry Analysis

HO1

Industry Average

Valuation HO1 Industry Range
Price/Earnings 89.2x
Price/Sales 4.4x
Price/Book 5.2x
Price/Cash Flow 21.3x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOLOGIC INC, please visit www.hologic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.